Arcus Biosciences Inc
NYSE:RCUS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.69
20.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Arcus Biosciences Inc
Arcus Biosciences Inc
Net Change in Cash
Arcus Biosciences Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Net Change in Cash
$17m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$669m
|
CAGR 3-Years
57%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$25.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-116%
|
CAGR 10-Years
-19%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$5.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$148.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Arcus Biosciences Inc
Glance View
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 366 full-time employees. The company went IPO on 2018-03-15. The firm's six investigational products are in the clinical development, with its molecule, an anti-TIGIT antibody, which is in two phase III registrational studies. The firm's differentiated combination therapies are developing to treat multiple large tumor types, including lung, colorectal, prostate and pancreatic cancers. Its clinical development pipeline includes Domvanalimab, AB308, Etrumadenant, Quemliclustat, Zimberelimab and AB521. Domvanalimab is its Fc-silent anti-TIGIT monoclonal antibody. AB308 is its Fc-enabled anti-TIGIT monoclonal antibody. Etrumadenant is designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors. Quemliclustat is an extremely potent and selective small-molecule CD73 inhibitor. Zimberelimab is its anti-PD-1 antibody.
See Also
What is Arcus Biosciences Inc's Net Change in Cash?
Net Change in Cash
17m
USD
Based on the financial report for Sep 30, 2024, Arcus Biosciences Inc's Net Change in Cash amounts to 17m USD.
What is Arcus Biosciences Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
32%
You don't have any saved screeners yet
